The diagnosis of coexisting AL-CA and wild-type transthyretin cardiac amyloidosis was confirmed through a combination of echocardiography, blood tests, cardiovascular magnetic resonance imaging, technetium-99m pyrophosphate scintigraphy, invasive procedures (bone marrow and endomyocardial biopsies), mass spectrometry, and genetic testing. This evidence concerns the gene TTR and cardiac amyloidosis.